Since its introduction in 1997, the Mini-gastric bypass (MGB) has become an increasingly popular bariatric procedure throughout the world. Despite published data over the following decades demonstrating comparable results to the Roux-en-Y bypass (RYB), the MGB has remained polarizing within the bariatric community. Over the past 5 years there has been growing popularity of the MGB is Australia due to its shorter operative time, positive learning curve and favorable side effect profile. This study investigates the early results for the MGB in an Australian setting.
We present a retrospective study of the first 101 consecutive laparoscopic MGBs performed between March 2014 and May 2017 by two bariatric surgeons. Medical records were reviewed to ascertain pre surgery weight, metabolic conditions, demographic information, history of previous bariatric surgery and bypass length. Weight loss, resolution of metabolic conditions, short and long term complications and other adverse effects were analysed.
101 patients (42 male, 59 female) were reviewed with a mean follow up of 302 days (Shortest follow up 7 days, longest 1079 days). 59 patients (58.4%) had preoperative metabolic syndrome requiring medication and 43 of these patients (72.8%) had significant reduction in or cessation of medications postoperatively. Patients who were followed up for a year or more (n =37) had a mean weight loss of 79.23% of excess weight (mean follow up 550 days). 9 (8.9%) patients suffered significant complications including gastric pouch leak (2), marginal ulcer (2), anastomotic stricture (2), late conversion to RYB (2) and relook laparoscopy for bleeding (1).
The MGB is a safe and effective bariatric procedure. Our early results show promising weight loss and resolution of metabolic conditions, with a low incidence of perioperative complications. The MGB should be considered a valuable component of the modern bariatric surgeon’s repertoire.